Propentofylline enhances cerebral metabolic response to auditory memory stimulation in Alzheimer's disease

Journal of the Neurological Sciences

Volumn 154, Issue 1, 1998, Pages 76-82

  Mielke, R ^a   Ghaemi, M ^a   Kessler, J ^a   Kittner, B ^b   Szelies, B ^a   Herholz, K ^a   Heiss, W D ^a  

^a MAX PLANCK INSTITUTE FOR NEUROLOGICAL RESEARCH   (Germany)

^b SANOFI   (France)

Author keywords

Alzheimer's disease; Brain activation; Nerve growth factor; Propentofylline; Regional cerebral glucose metabolism; Reserve capacity

Indexed keywords

PLACEBO; PROPENTOFYLLINE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; HUMAN; MEMORY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ACOUSTIC STIMULATION; ADULT; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANALYSIS OF VARIANCE; BRAIN; DOUBLE-BLIND METHOD; FEMALE; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; GLUCOSE; HUMANS; MALE; MEMORY; MIDDLE AGED; NEUROPROTECTIVE AGENTS; PROSPECTIVE STUDIES; PSYCHOMETRICS; TOMOGRAPHY, EMISSION-COMPUTED; XANTHINES;

EID: 0032554044     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-510X(97)00217-7     Document Type: Article

References (42)

1. American Psychiatric Association, 1987. Diagnostic and Statistical Manual of Mental Disorders, third edition, revised. American Psychiatric Association, Washington DC.
2. Banati R.B., Schubert P., Rothe G., Gehrmann J., Rudolphi K., Valet G., Kreutzberg G.W. Modulation of intracellular formation of reactive oxygen intermediates in peritoneal macrophages and microglia/brain macrophages by HWA 285. J. Cereb. Blood Flow Metab. 14:1994;145-149.
3. Bartus R.T., Dean R.L., Beer R.et al. Cholinergic hypothesis of geriatric memory dysfunction. Science. 217:1982;408-416.
4. Baschek I.L., Bredenkamp J., Oehrle B., Wippich W. Bestimmung der Bildhaftigkeit (I), Konkretheit (C) und der Bedeutungshaltigkeit (m′) von 800 Substantiven. Z. Exp. Angew. Psychol. 24:1977;353-396.
5. Boller F., Becker J.T., Holland A.L., Forbes M.M., Hood P.C., McGonigle-Gibson K.L. Predictors of decline in Alzheimer's disease. Cortex. 27:1991;9-17.
6. Dickson D.W., Lee S.C., Mattiace L.A., Yen S.C., Brosnan C. Microglia and cytokines in neurological disease, with special reference to AIDS and Alzheimer's disease. Glia. 7:1993;75-83.
7. Duara R., Barker W.W., Chang J., Yoshii F., Loewenstein D.A., Pascal S. Viability of neocortical function shown in behavioral activation state PET studies in Alzheimer disease. J. Cereb. Blood Flow Metab. 12:1992;927-934.
8. Eagger S.A., Harvey R.J. Clinical heterogeneity-responders to cholinergic therapy. Alzheimer Dis. Assoc. Disord. 9:1995;37-42.
9. Folstein M.F., Folstein S.E., McHugh P.R. 'Mini-Mental-State' - a practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 12:1975;189-198.
10. Gnahn H., Hefti F., Heumann R., Schwab M.E., Thoenen H. NGF-mediated increase of choline acetyltransferase (ChAT) in the neonatal rat forebrain: evidence for a physiological role of NGF in the brain. Brain Res. 285:1983;45-52.
11. Goto M., Demura N., Sakaguchi T. Effects of propentofylline on disorder of learning and memory in rodents. Jpn. J. Pharmacol. 45:1987;373-378.
12. Grady C.L., Haxby J.V., Horwitz B., Gillette J., Salerno J.A., Gonzalez-Aviles A., Carson R.E., Herscovitch P., Schapiro M.B., Rapoport S.I. Activation of cerebral blood flow during a visuoperceptual task in patients with Alzheimer-type dementia. Neurobiol. Aging. 14:1993;35-44.
13. Green, D.M., Swets, J.A., 1966. Signal Detection Theory and Psychophysics. Wiley, New York.
14. Hachinski V.C., Linnette D.I., Zilhka E., DuBoulay G.H., McAllister V.L., Marshall J., Russell R.W.R., Symon L. Cerebral blood flow in dementia. Arch. Neurol. 32:1975;632-637.
15. Hefti F., Dravid A., Hartikka J. Chronic intraventricular injections of nerve growth factor elevate hippocampal choline acetyltransferase activity in adult rats with partial septo-hippocampal lesions. Brain Res. 293:1984;305.
16. Heiss W.D., Hebold I., Klinkhammer P., Ziffling P., Szelies B., Pawlik G., Herholz K. Effect of piracetam on cerebral glucose metabolism in Alzheimer's disease as measured by positron emission tomography. J. Cereb. Blood Flow Metab. 8:1988;613-617.
17. Katzman R., Brown T., Thal L.J., Fuld P.A., Aronson M., Butters N., Klaunber M.R., Wiederholt W., Pay M., Renbing X., Ooi W.L., Hofstetter R., Terry R.D. Comparison of rate of annual change of mental score in four independent studies of patients with Alzheimer's disease. Ann. Neurol. 24:1988;384-389.
18. Kessler J., Herholz K., Heiss W.D. Impaired metabolic activation in Alzheimer's disease: a PET study during continous visual recognition. Neuropsychologia. 29:1991;229-243.
19. Kiss J., McGovern J., Patel A.J. Immunohistochemical localization of cells containing nerve growth factor receptors in the different regions of the adult forebrain. Neuroscience. 27:1988;731-748.
20. Klinkhammer P., Szelies B., Heiss W.D. Effect of phosphatidylserine on cerebral glucose metabolism in Alzheimer's disease. Dementia. 1:1990;197-201.
21. Kromer L.F. Nerve growth factor treatment after brain injury prevents neuronal death. Science. 235:1987;214-216.
22. Marcusson J. European Propentofylline Study Group. HWA 285 for the treatment of dementia - results of a 12 months clinical trial. J. Cereb. Blood Flow Metab. 15:1995;107.
23. Matsui, T., Hirano, A. (Eds.), 1978. An Atlas of the Human Brain for Computerized Tomography. Fischer, Stuttgart/Tokyo/New York.
24. Mattiace L.A., Davies P., Yen S.H., Dickson D.W. Microglia in cerebellar plaques in Alzheimer's disease. Acta Neuropathol. 80:1990;493-498.
25. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology. 19:1984;939-944.
26. Mielke R., Herholz K., Grond M., Kessler J., Heiss W.D. Clinical deterioration in probable Alzheimer's disease correlates with progressive metabolic impairment of association areas. Dementia. 5:1994;36-41.
27. Mielke R., Ghaemi M., Kittner B., Kessler J., Szelies B., Herholz K., Heiss W.D. Propentofylline improves regional cerebral glucose metabolism and neuropsychologic performance in vascular dementia. J. Neurol. Sci. 141:1996;59-64.
28. Miller J.D., de Leon M.J., Ferris S.H., Kluger A., George A.E., Reisberg B., Sachs H.J., Wolf A.P. Abnormal temporal lobe response in Alzheimer's disease during cognitive processing as measured by 11C-2-deoxy-D-glucose and PET. J. Cereb. Blood Flow Metab. 7:1987;248-251.
29. Mobley W.C., Rutkowski J.L., Tennekoon G.I., Buchanan K., Johnston M.V. Choline acetyltransferase activity in striatum of neonatal rats increased by nerve growth factor. Science. 229:1985;284-287.
30. Nabeshima T., Nitta A., Hasegawa T. Impairment of learning and memory and the accesory symptoms in aged rats as senile dementia model: oral administration of HWA 285 produces recovery of reduced NGF content in the brain of aged rats. Jpn. J. Psychopharmacol. 13:1993;89-95.
31. Oswald W.D. Psychometrische Verfahren und Fragebögen für gerontopsychologische Untersuchungen. Z. Gerontol. 12:1979;341-350.
32. Parnetti L. Clinical pharmacokinetics of drugs for Alzheimer's disease. Clin. Pharmacokinet. 29:1995;110-129.
33. Rapoport S.I. Positron emission tomography in Alzheimer's disease in relation to disease pathogenesis: a critical review. Cerebrovasc. Brain Metab. Rev. 3:1991;297-335.
34. Riopelle R.J., Richardson P.M., Verge V. Distribution and characteristics of nerve growth factor binding on cholinergic neurons of rat and monkey forebrain. Neurochem. Res. 12:1987;923-928.
35. Saletu B., Möller H.J., Grünberger J., Deutsch H., Rössner M. Propentofylline in adult-onset cognitive disorders: double-blind, placebo controlled, clinical, psychometric and brain mapping studies. Neuropsychobiology. 24:1990;173-184.
36. Salmon D.P., Thal L.J., Butters N., Heindel W.C. Longitudinal evaluation of dementia of the Alzheimer type: a comparison of 3 standardized mental status examinations. Neurology. 40:1990;1225-1230.
37. Schaaf, A., Kessler, J., Grond, M., Fink, G., 1992. Memo Test. Ein verbaler Gedächtnistest nach der Methode des selektiven Erinnerns. Beltz-Test-Verlag, Weinheim.
38. Shinoda I., Fukura Y., Fukura S. Stimulation of nerve growth factor synthesis/secretion by propentofylline in cultured mouse astroglial cells. Biochem. Pharmacol. 39:1990;1813-1816.
39. Spreen, O., Strauss, E., 1991. A Compendium of Neuropsychological Tests. Oxford University Press, New York/Oxford, pp. 221-229.
40. Wienhard K., Pawlik G., Herholz K., Wagner R., Heiss W.D. Estimation of local cerebral glucose utilization by positron emission tomography of (18F)-2-fluoro-2-deoxy-D-glucose: A critical appraisal of optimization procedures. J. Cereb. Blood Flow Metab. 5:1985;115-125.
41. Wienhard K., Eriksson L., Grootonk S., Casey M., Pietrzyk U., Heiss W.D. Performance evaluation of the positron scanner ECAT EXACT. J. Comput. Assist. Tomogr. 16:1992;804-813.
42. Yamada Y., Nakamura H., Okada Y. HWA 285 enhances the formation of long-term potentiation in guinea pig hippocampal slices. Neurosci. Lett. 176:1994;189-192.